Status:
NOT_YET_RECRUITING
The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
Lead Sponsor:
Fudan University
Collaborating Sponsors:
Shanghai Zhongshan Hospital
Ruijin Hospital
Conditions:
Hepatocellular Carcinoma
Colorectal Cancer Liver Metastasis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Multimodal thermal therapy (MTT), as an initiative integration of cryotherapy and radiofrequency heating, has been applied to treat various solid tumors. The feasibility and safety for MTT in the trea...
Eligibility Criteria
Inclusion
- Age of 18-75 years.
- Clinical diagnosis or pathologic of hepatocellular carcinoma (HCC) or metastatic liver cancers.
- Intrahepatic lesions with a diameter of ≤5cm, and the number of lesions ≤5.
- Without extrahepatic metastases; for patients with liver metastases, previously underwent radical resection of the primary lesion without local recurrence.
- Child-Pugh score ≤7 (Class A or B).
- Performance status 0-1 (Eastern Cooperative Oncology Group classification).
- Life expectancy of at least 3 months.
- Patients who have previously undergone surgery, chemotherapy, targeted therapy, ablation, vascular interventional therapy (TACE, D-TACE, HAIC), or immunotherapy, with an interval of ≥3 weeks since the last treatment.
- The functional level of major organs must meet the following requirements:
- (1) Blood Routine: WBC≥3.0×109/L，ANC≥1.5×109/L，PLT≥50×109/L，HGB≥90 g/L. (2) Liver Function: AST ≤5.0×ULN, ALT ≤5.0×ULN, TBIL ≤2.0×ULN. (3) Renal Function: Cr ≤1.5×ULN or CrCl ≥60 mL/min. (4) Coagulation Function: INR ≤1.5; APTT ≤1.5×ULN. (5) HBV-DNA: HBV-DNA ≤2×10³ IU/mL (\*Patients with HBV-DNA \>2×10³ IU/mL may be enrolled but must receive antiviral therapy.\*)
Exclusion
- Diffuse hepatocellular carcinoma (HCC), or with tumor thrombus in the main portal vein to secondary branches or hepatic veins.
- Severe liver atrophy or excessively large tumor volume requiring ablation of ≥1/3 of the liver volume.
- Uncorrectable coagulation dysfunction or severe hematologic abnormalities with a high risk of bleeding.
- Active bacterial infection or fungal infection.
- Previous or coexisting malignancies.
- History of solid organ transplant or hepatic encephalopathy.
- Current enrollment in another clinical trial or prior exposure to experimental therapies.
- Pregnant or breastfeeding, or preparing to pregnant.
- Not suitable to participate in clinical trials judged by investigator.
Key Trial Info
Start Date :
September 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07159048
Start Date
September 10 2025
End Date
October 31 2027
Last Update
September 8 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.